| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Scinai Immunotherapeutics Ltd.
$0.25
0 (-0.07%)
Market Cap
970.66 K
EPS
-10.26
P/E Ratio
-
Value Trade
83.74 K
SEC Financials
Q1 2023Dilution Risk
R&D Expenses
2.00 M
Operating CF
-3.06 M
Total Assets
23.29 M
Total Liabilities
23.29 M
Equity
-4.81 M
-10.15 %
Week
1.78 %
1 Month
-52.13 %
3 Month
-68.95 %
6 Month
-99.84 %
5 Year
-99.91 %
All Time
Cash Data
Cash Position
10.80 M
Monthly Burn
1.02 M
Runway
0 mo
Burn Trend
SEC Filing
May 15, 2023
Overview
Volume
21.67 K
52 Week Range
0.21 - 1.97
% held by Insiders
2.25 %
% held by Institutions
0.68 %
Enterprise Value
-9.83 M
Total Shares
3.96 M
Short %
11.76 %
Float Shares
3.39 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Scinai Immunotherapeutics Ltd.
432Total events
9Upcoming
69Tier-1 (high impact)
2015 – 2026Coverage
Upcoming catalysts 2
TBD
T1Partnership / License
Subscribe to view catalyst details
TBD
T1Partnership / License
Subscribe to view catalyst details
Event history 2
TBD
◆Manufacturing MilestoneCMC / Inspection
Subscribe to view catalyst details
TBD
◆FDA Feedback ReceivedIL-17FDA Meeting
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
anti-IL-17 NanoAbs | mild to moderate plaque psoriasis | — | 2023-12-12 | significantly reduced IL-17 release (p<0.001); improved skin structure following a single dose; more efficient than Betamethasone in reducing inflammation-induced skin; at least as efficient as Cosentyx Read More | Scinai Announces Promising Results in a Psoriatic Human Skin Model Read More | |
anti-IL-17 NanoAbs | mild to moderate plaque psoriasis | — | 2023-12-12 | significantly reduced IL-17 release (p<0.001); improved skin structure following a single dose; more efficient than Betamethasone in reducing inflammation-induced skin; at least as efficient as Cosentyx Read More | Scinai Announces Promising Results in a Psoriatic Human Skin Model Read More | |
anti-IL-17 NanoAbs | mild to moderate plaque psoriasis | — | 2023-12-12 | significantly reduced IL-17 release (p<0.001); improved skin structure following a single dose; more efficient than Betamethasone in reducing inflammation-induced skin; at least as efficient as Cosentyx Read More | Scinai Announces Promising Results in a Psoriatic Human Skin Model Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SCNI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SCNI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SCNI▼ -0.1%today
Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration
Scinai Immunotherapeutics has appointed Eran Kuratz as Head of Supply Chain and Business Process Administration for its CDMO subsidiary. Kuratz, with over 30 years of experience, will lead key operational functions to support the company's expanded CDMO platform. This appointment follows Scinai's recent acquisition of Recipharm Israel, enhancing its development and manufacturing capabilities.
Read more →SCNI▼ -7.7%on this news
Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives
Scinai Immunotherapeutics Ltd. reported its financial results for Q1 2026, highlighting a net income of $3.6 million following the acquisition of Recipharm Israel. The company expanded its CDMO platform, enhancing its manufacturing capabilities and strategic collaborations. However, operating losses increased due to higher expenses associated with the expansion, and revenues saw a decline compared to the previous year.
Read more →SCNI▼ -6%on this news
Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility
Scinai Immunotherapeutics has appointed Eilon Elmalem as the Site Head of its Yavne CDMO facility, effective June 14, 2026. Elmalem, who has been an external consultant for two years, will oversee site operations and engineering activities. The transition process is under the supervision of the current site head, Dr. Sylvia Kachalsky, who is set to retire later in 2026.
Read more →SCNIScinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe
Scinai Immunotherapeutics will lead a roundtable at the 7th Dermatology Drug Development Summit Europe, discussing the impact of oral therapies on biologics. The session will address key questions regarding the efficacy and strategic role of oral peptide and small molecule therapies in immunology. CEO Amir Reichman emphasizes the importance of these discussions for the future of immunology treatments.
Read more →SCNISCINAI IMMUNOTHERAPEUTICS LTD. Jerusalem BioPark, 2 nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held on
Scinai Immunotherapeutics Ltd. announced the scheduling of its Annual General Meeting of Shareholders, which will take place on June 16, 2026, in Tel Aviv, Israel. Shareholders who hold American Depositary Shares (ADSs) on May 13, 2026, will be entitled to attend and vote. The meeting will provide an opportunity for ADS holders to review financial statements for the fiscal year ended December 31, 2025. The proxy materials recommend a "FOR" vote on various proposals, although no additional matters are currently anticipated for discussion.
Read more →SCNIRecipharm Israel Ltd. Audited Financial Statements as of
Recipharm Israel Ltd. has released its audited financial statements for the year ending December 31, 2025, reporting significant losses and a negative equity position. The company experienced a comprehensive loss of NIS 9,395 thousand and reported a working capital deficit of NIS 22,819 thousand. Concerns regarding the company's ability to continue as a going concern have been raised due to its reliance on support from its parent company, Recipharm OT AB. The financial statements reflect a challenging fiscal situation for the company.
Read more →SCNI▲ +61.6%on this news
Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing
Scinai Immunotherapeutics Ltd. has announced a $2.61 million private placement financing led by an institutional investor. The funds will be used to expand its contract development and manufacturing organization (CDMO) platform and advance customer programs. The closing of the transaction is expected around April 27, 2026, subject to customary conditions.
Read more →SCNIScinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities
Scinai Immunotherapeutics has completed a strategic reorganization to create a dedicated CDMO platform, Scinai Biopharma Services, and streamline its R&D operations. This transformation aims to enhance capital efficiency and operational focus, allowing both divisions to operate independently. The company targets approximately $5 million in CDMO revenues for 2026 while advancing key R&D programs.
Read more →SCNI▲ +12.1%on this newsshared move
Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration
Scinai Immunotherapeutics reported a doubling of CDMO revenues to $1.3 million for the year ended December 31, 2025. The company expanded its capabilities through the acquisition of Recipharm Israel and a strategic collaboration, enhancing its manufacturing services. Despite a net loss of $8.3 million, Scinai is focusing on capital-efficient funding and positioning its lead program, PC111, for growth.
Read more →SCNIScinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026
Scinai Immunotherapeutics Ltd. will participate in BIO-Europe Spring 2026, highlighting its enhanced contract development and manufacturing organization (CDMO) following the acquisition of Recipharm Israel. The company aims to engage with pharmaceutical and biotechnology firms to advance its R&D pipeline of innovative antibody-based immunotherapies. Scinai is positioning itself as a flexible partner in the development to commercialization continuum. However, the outlook includes risks related to the recent acquisition and operational integration challenges.
Read more →SCNIScinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price
Scinai Immunotherapeutics Ltd. received notice from NASDAQ regarding non-compliance with minimum bid price requirements, as their American Depositary Shares (ADSs) traded below $1.00 for 30 business days. The company has 180 days to regain compliance, providing they maintain the bid price above $1.00 for ten consecutive days. Despite the notification, there is no immediate effect on the trading of their ADSs. Scinai is evaluating its options to meet the listing requirements.
Read more →SCNIScinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept
Scinai Immunotherapeutics has signed a Second Amendment to its option agreement for acquiring PinCell S.r.l. and submitted a revised application for €12 million in non-dilutive funding to support its PC111 program. The funding aims to advance PC111, a monoclonal antibody for autoimmune diseases, through early clinical development. The revised application reflects enhancements to project design, with expectations for a funding decision in three to four months.
Read more →SCNI▲ +5.9%on this newsshared move
Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform
Scinai Immunotherapeutics has received expanded support from the Israel Innovation Authority for its robotic aseptic fill and finish platform, with a total grant of NIS 5 million. This funding will aid in acquiring and validating a fully automated system to meet EU GMP standards. The initiative is part of Scinai's strategy to enhance its CDMO capabilities following its acquisition of Recipharm Israel Ltd. and aims to improve sterile manufacturing processes.
Read more →SCNIScinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm
Scinai Immunotherapeutics Ltd. has successfully acquired Recipharm Israel Ltd., significantly enhancing its manufacturing capabilities and expanding its CDMO footprint in Israel. This acquisition is complemented by a long-term strategic commercial collaboration with Recipharm, which will streamline transitions for clients from early-stage development to late-stage manufacturing. The collaboration aims to improve service delivery, manage quality, and reduce costs. Scinai's CEO emphasized the importance of this acquisition in creating an integrated product development pathway and ensuring continuity for Recipharm’s employees and clients.
Read more →SCNIScinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL
Scinai Immunotherapeutics' CEO, Amir Reichman, will co-lead a roundtable at HealthIL Week 2026 focused on biopharma manufacturing in Israel. The discussion aims to address the capabilities and gaps in the country's biopharma ecosystem, emphasizing early-stage development and regulatory readiness. Key stakeholders, including government representatives and biopharma manufacturers, are expected to participate.
Read more →SCNIScinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances
Scinai Immunotherapeutics reported its financial results for the nine months ending September 30, 2025, highlighting growth in its CDMO business and advancements in its NanoAbs pipeline. The company is actively pursuing partnerships and has submitted grant applications to support its research programs. However, it faced a setback with the non-approval of a significant grant for its PC111 program, prompting a review of its strategic options.
Read more →SCNIScinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities
Scinai Immunotherapeutics has been awarded a grant from the Israel Innovation Authority to enhance its fill-and-finish capabilities. The funding will support a project aimed at acquiring advanced manufacturing systems, addressing a significant gap for early-stage biotech firms. This expansion is expected to improve operational flexibility and capacity, benefiting clients in Israel and abroad.
Read more →SCNISTANDBY EQUITY PURCHASE AGREEMENT THIS STANDBY EQUITY PURCHASE AGREEMENT (this " Agreement ") dated as of
SCINAI Immunotherapeutics Ltd. has entered into a Standby Equity Purchase Agreement with YA II PN, LTD., allowing the company to issue and sell up to $15 million worth of American Depository Shares (ADSs). This agreement is structured to give the investor the right to purchase ADSs over time, which could positively impact the company's funding and market position. The ADSs are traded on the Nasdaq under the ticker SCNI, reflecting the company's commitment to utilizing capital markets effectively.
Read more →SCNIScinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet
Scinai Immunotherapeutics Ltd. reported its financial results for the six months ending June 30, 2025, showcasing significant growth in its CDMO services and a robust balance sheet. The company continues to focus on developing innovative biological drug candidates for inflammation and immunology-related diseases. However, it faces several risks, including compliance issues and potential delays in clinical trials.
Read more →SCNIScinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN
Scinai Immunotherapeutics announced a new peer-reviewed publication confirming the efficacy of PC111, a human anti-Fas Ligand monoclonal antibody, as a disease-modifying therapy for pemphigus and SJS/TEN. The study demonstrates PC111's ability to prevent blister formation and offers a non-immunosuppressive treatment option. The company plans to advance PC111 into clinical development, targeting a market opportunity exceeding one billion dollars.
Read more →SCNIScinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives "Oscar of Italian Dermatology"
Scinai Immunotherapeutics announced that Dr. Roberta Lotti received the prestigious "Oscar of Italian Dermatology" for her research on PC111, an anti-Fas Ligand monoclonal antibody. This recognition underscores the potential of PC111 in treating pemphigus vulgaris and other severe autoimmune conditions. The award supports Scinai's strategic option agreement to acquire Pincell, enhancing its immunology pipeline.
Read more →SCNIScinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025
Scinai Immunotherapeutics Ltd. announced its participation in the BIO International Convention 2025, where CEO Amir Reichman will meet with investors and partners. The company recently raised $1.38 million to support its CDMO growth and R&D efforts, with 2025 revenue guidance of $2 million. Scinai is also implementing cost reduction strategies to enhance financial stability.
Read more →SCNI▼ -26.5%on this news· ran to -42% by day 1
Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.
Scinai Immunotherapeutics has received Italian government clearance under the Golden Power regulation for its potential acquisition of Pincell S.r.l. This approval allows Scinai to move forward with the transaction, although it remains subject to customary conditions. Pincell's lead candidate, PC111, is in development for severe dermatological conditions and has received Orphan Drug Designation.
Read more →SCNI▼ -8.1%on this news· ran to +19% by day 3shared move
Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn JERUSALEM, May 30th, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ( Scinai , or the Company )
Scinai Immunotherapeutics Ltd. reported its Q1 2025 financial results, highlighting strong growth in its Contract Development and Manufacturing Organization (CDMO) revenue. The company also successfully reduced cash burn, indicating improved financial management. However, there are concerns regarding decreased cash reserves compared to the previous year, as well as risks associated with potential delays in clinical studies and the ability to secure additional funding for future operations.
Read more →SCNIScinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn
Scinai Immunotherapeutics Ltd. reported its Q1 2025 financial results, highlighting a strong momentum in its Contract Development and Manufacturing Organization (CDMO) services and a reduction in cash burn compared to the previous year. The company continues to focus on developing innovative biological drug candidates for inflammation and immunology-related diseases. However, it faces challenges such as anticipated lower revenues and potential delays in clinical studies.
Read more →SCNIScinai Announces Annual Financial Results for 2024
Scinai Immunotherapeutics Ltd. announced its annual financial results for 2024, revealing a decrease in cash and equivalents from $4.9 million to $1.9 million. The company focuses on developing innovative therapies for inflammation and immunology-related diseases and provides CDMO services. The report highlights various risks, including compliance and potential delays in clinical trials.
Read more →SCNIScinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases
Scinai Immunotherapeutics is set to host a webinar on May 7, 2025, to discuss PC111, a novel monoclonal antibody drug candidate. This drug has the potential to transform treatment for Pemphigus Vulgaris and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. The webinar will focus on the unmet needs in these conditions and how PC111 could address them.
Read more →SCNI▼ -14.8%on this news
Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions
Scinai Immunotherapeutics has signed an option agreement to acquire Pincell, a biotech firm focused on developing the monoclonal antibody PC111 for the treatment of severe dermatological conditions like Pemphigus, SJS, and TEN. This agreement follows a jointly submitted grant application seeking Euro 12 million to further develop PC111, which has shown promise in clinical settings without the use of immunosuppressive agents. PC111 has already received Orphan Drug Designation from the European Medicines Agency, and Scinai plans to file for similar designations in the U.S. The partnership aims to leverage both companies' expertise to expedite the drug's development journey.
Read more →SCNIScinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) will connect with investors and showcase its innovative inflammation and immunology (I&I) pipeline at the BIO-Europe Spring 2025 conference in Milan, Italy. The company's leadership is set to engage with potential pharmaceutical partners and clients interested in its CDMO services. Scinai has launched its CDMO business, which aims to support early-stage biotech companies with essential biologics development services. The company emphasizes its compliance with cGMP conditions and the need for such services in the market.
Read more →SCNISCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10
Scinai Immunotherapeutics has entered into a $10 million Standby Equity Purchase Agreement with Yorkville Advisors that allows the company to sell its American Depository Shares over a three-year period. This agreement provides Scinai with flexibility and control over capital raising without any mandatory obligations. The funds raised will be directed towards the development of its NanoAbs products and supporting its contract development manufacturing operations. Despite the favorable terms, there are inherent risks including lower anticipated revenues and the uncertainty surrounding the commercialization of NanoAbs.
Read more →SCNISCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT
Scinai Immunotherapeutics Ltd. has announced a $10 million Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. This agreement allows Scinai the flexibility to sell its American Depository Shares at a 3% discount to market prices, aiming to fund its research and development programs and expand its CDMO services. The terms of the SEPA are favorable and provide Scinai with control over the timing and amount of any sales. However, the company does face uncertainties regarding the realization of anticipated capital and performance in its business ventures.
Read more →SCNIScinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences
Scinai Immunotherapeutics Ltd. will be represented by CEO Amir Reichman and Chairman Mark Germain at several upcoming conferences, including the IATI Mini Mixiii Conference and the JP Morgan HealthCare Conference. The meetings aim to attract institutional and private investors and discuss potential partnerships in the inflammation and immunology sector. The company has recently released a year-end video that outlines its achievements in 2024, promoting its innovative products and CDMO services.
Read more →SCNIScinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.
Scinai Immunotherapeutics has established a U.S.-based subsidiary, Scinai Bioservices Inc., to enhance its Contract Development and Manufacturing Services. This expansion comes amid increasing demand for CDMO services in the U.S. targeted at early-stage biotech companies. The new subsidiary aims to address a supply void while complying with new legislation that could affect foreign collaborations. The company has already signed its first contract with Serpin Pharma, indicating a strong start in the competitive U.S. market.
Read more →SCNIProf. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. has appointed Prof. Michael Schön, a leading figure in dermatology at the University Medical Center Göttingen, to its Scientific Advisory Board. Prof. Schön's extensive research background and expertise in chronic inflammatory skin diseases will contribute significantly to Scinai's innovative pipeline. The company aims to leverage his insights to advance its development of I&I biological products. Additionally, CEO Amir Reichman expressed enthusiasm for the appointment, highlighting the importance of such talent in enhancing Scinai's R&D endeavors.
Read more →SCNIDr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics
Scinai Immunotherapeutics has appointed Dr. Jonathan Sadeh, former Senior VP of Immunology R&D at Bristol-Myers Squibb, to its Scientific Advisory Board. Dr. Sadeh brings over 20 years of experience in drug development and clinical research, having overseen various successful drug approvals. His involvement is anticipated to advance Scinai's clinical programs, particularly its IL-17 initiative. The company aims to leverage unique attributes of VHH antibodies to provide innovative therapies to patients with high unmet medical needs.
Read more →SCNIScinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of
Scinai Immunotherapeutics Ltd. announced a significant positive shift in shareholders' equity, rising to $10 million after a restructuring of its loan with the European Investment Bank. The company also regained compliance with Nasdaq requirements and reported promising results from its pre-clinical proof of concept study for treating plaque psoriasis. Additionally, Scinai is actively pursuing growth opportunities in its contract development and manufacturing organization business. However, it faces ongoing challenges, including a notable decrease in cash resources compared to the previous year.
Read more →SCNI▲ +17.2%on this newsshared move
Scinai Publishes Financial Results and Provides Business Update; Shareholders
Scinai Immunotherapeutics Ltd. has released its financial results for the nine months ending September 30, 2024, highlighting a significant increase in shareholder equity following the conversion of an EIB loan into equity. The company regained compliance with Nasdaq's equity requirements and has initiated CDMO operations, expecting to generate meaningful revenues. Additionally, promising developments in their drug pipeline, particularly for treating plaque psoriasis, have been reported, with a clinical trial anticipated to commence in the latter half of 2025.
Read more →SCNIScinai Leadership to Showcase Company
Scinai Immunotherapeutics Ltd. will highlight its innovative inflammation and immunology product pipeline at BIO-Europe 2024 in Stockholm, Sweden. At the conference, the company's leadership will engage with prospective clients and partners, showcasing its end-to-end biologics CDMO services. Scinai aims to attract interest for co-developing its NanoAbs technology and pursuing collaboration in psoriasis drug development. However, the company faces various risks, including potential delays in clinical studies and signing new client agreements.
Read more →SCNISCINAI IMMUNOTHERAPEUTICS LTD. Jerusalem BioPark, 2 nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held on November 21, 2024 The Annual General Meeting
Scinai Immunotherapeutics Ltd. has announced its Annual General Meeting of Shareholders, set for November 21, 2024, in Tel Aviv, Israel. Key agenda items include the re-election of board members, amendments to the Articles of Association to increase authorized ordinary shares, and the appointment of auditors for the year 2024. Shareholders are encouraged to vote via proxy if they cannot attend in person. The meeting will provide an opportunity to review the company's financial statements for the fiscal year ended December 31, 2023.
Read more →SCNIScinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies
Scinai Immunotherapeutics Ltd. is set to host a scientific webinar on September 18, 2024, focusing on new treatment options for mild to moderate plaque psoriasis. The panel will include key experts discussing the potential of Scinai's anti-IL-17A/F VHH antibody for intralesional injections. Aspects of the discussion will cover existing treatment gaps and the biological drug development journey. The event highlights Scinai's commitment to addressing unmet medical needs in dermatology.
Read more →SCNI▼ -7.5%on this news
Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23 JERUSALEM
Scinai Immunotherapeutics Ltd. has published its financial results for Q2 2024 and announced a successful restructuring of a $29 million bank loan into equity, enabling them to comply with Nasdaq's requirements. The company's planned restructuring is aimed at regaining compliance by August 23, 2024. Alongside this financial update, Scinai remains optimistic about its sales guidance of $1.25 million for 2024 and is aggressively advancing its NanoAb development in the treatment of plaque psoriasis, showing promising preliminary results in recent studies.
Read more →SCNIScinai Regains Full Compliance with Nasdaq Listing Requirements
Scinai Immunotherapeutics Ltd. announced on August 27, 2024, that it has regained compliance with Nasdaq Listing Requirements after addressing its financial situation. The company converted approximately $29 million of debt into preferred equity, resulting in stockholders' equity exceeding $2.5 million. CEO Amir Reichman highlighted the importance of this turnaround and expressed optimism for future growth, particularly in R&D and their new CDMO business unit. However, Scinai will be under a one-year Mandatory Panel Monitor to ensure ongoing compliance.
Read more →SCNIScinai Regains Full Compliance with Nasdaq Listing Requirements Jerusalem, ISRAEL - aUGUST 29 , 2024 - Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI; "Scinai", or the "Company"), a biopharmaceutical company focused on dev
Scinai Immunotherapeutics Ltd. has announced that it has regained full compliance with Nasdaq listing requirements, following a successful debt restructuring that converted approximately $29 million of debt to equity. This change has increased the company's stockholders' equity to above the required $2.5 million. CEO Amir Reichman expressed optimism about the company's future, stating that this achievement allows Scinai to concentrate more on its research and development programs and CDMO services. However, the company is now under a mandatory monitoring period by Nasdaq for one year.
Read more →SCNIScinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000
Scinai Immunotherapeutics Ltd. has successfully closed a loan restructuring agreement with the European Investment Bank, converting approximately $29 million of debt into preferred equity. As a result, the company's outstanding debt is reduced to approximately $273,000, allowing it to regain compliance with Nasdaq listing requirements. The restructuring is expected to bolster Scinai's financial stability and enhance its capacity for future growth, particularly in its inflammation and immunology product development and CDMO services.
Read more →SCNIScinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder
Scinai Immunotherapeutics Ltd. has announced a $2 million Investment Commitment Agreement with RK Stone Miami LLC, its largest shareholder. This agreement allows Scinai to sell American Depository Shares (ADSs) to the investor over a specified period until the end of 2024. There are provisions in place that limit the number of shares the investor can acquire, ensuring compliance with ownership thresholds. This development marks a significant financial opportunity for Scinai, reflecting confidence from its major shareholder.
Read more →SCNIScinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23
Scinai Immunotherapeutics Ltd. has published its Q2 2024 financial results, highlighting successful restructuring of a $29 million bank loan into equity to regain Nasdaq compliance by August 23, 2024. The company has made strides in its product pipeline, demonstrating promising results in preclinical studies for its NanoAb treatment for plaque psoriasis. Additionally, the Company is seeing growth in its CDMO services and plans to host a webinar to further discuss business updates and financial performance.
Read more →SCNIScinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity
Scinai Immunotherapeutics Ltd. has entered into a loan restructuring agreement with the European Investment Bank to convert approximately $29 million of debt into preferred shares. This strategic move reduces their outstanding loan amount significantly and is aimed at stabilizing the company's financial foundation. The new preferred shares offer conversion options that equate to 19.5% ownership of the company's common equity, facilitating future growth in their therapeutic development efforts.
Read more →SCNI▼ -6.8%on this news
SCINAI IMMUNOTHERAPEUTICS LTD. Jerusalem BioPark, 2 nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel NOTICE TO SHAREHOLDERS RE. SUPPLEMENTAL CHANGES TO PROXY STATEMENT FOR EXTRAORDINARY GENERAL MEETING To Be Held on
Scinai Immunotherapeutics Ltd. is updating shareholders regarding changes to its Proxy Statement for an Extraordinary General Meeting set for August 12, 2024. The proposed amendments focus on the approval of preferred shares in connection with a debt-to-equity conversion with the European Investment Bank. Notable changes include a limitation on holdings to prevent conversion beyond 4.99% ownership. Additionally, amendments to veto rights for preferred shareholders aim to enhance the company's governance framework.
Read more →SCNIScinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb
Scinai Immunotherapeutics has received positive regulatory feedback from the Paul Erlich Institute (PEI) regarding its clinical development plan for the anti-IL-17A/F nanoAb (SCN-1) intended for treating mild to moderate plaque psoriasis. The PEI has agreed to the company's approach of using pig studies for toxicology, thus avoiding the necessity of testing in healthy volunteers. The upcoming Phase 1/2a trial will be designed to assess both safety and efficacy, allowing for direct comparisons with a placebo. The trial is projected to start in late 2025, targeting around 24 patients.
Read more →SCNI▲ +45.1%on this news
Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model
Scinai Immunotherapeutics has announced promising results from an in-vivo study of its anti IL-17A/F VHH antibody fragment, designed as a localized treatment for mild to moderate plaque psoriasis. This novel therapy aims to address shortcomings of current treatments, which are often systemic and have significant side effects. The preclinical trial showed that Scinai's NanoAb offers anti-inflammatory effects similar to existing therapies but with a more localized application, suggesting improved patient adherence and reduced risks. Future plans include dosing optimization and a longer duration follow-on study, leading to a first-in-human trial by late 2025.
Read more →SCNISCINAI IMMUNOTHERAPEUTICS LTD. Jerusalem BioPark, 2 nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel NOTICE OF EXTRAORDINARY MEETING OF SHAREHOLDERS To Be Held on August 12, 2024 An Extraordinary Meeting of Sh
Scinai Immunotherapeutics Ltd. has announced an Extraordinary Meeting of Shareholders scheduled for August 12, 2024, in Tel Aviv. The meeting will address key proposals, including amendments to authorize preferred shares and a grant of restricted share units to the CEO. Shareholders holding ordinary shares represented by American Depositary Shares are eligible to vote. The company emphasizes the importance of participation and clarifies the voting process for its shareholders.
Read more →SCNIScinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity
Scinai Immunotherapeutics Ltd. has received an updated Letter of Intent from the European Investment Bank (EIB) outlining terms to convert a significant portion of its loan into equity, specifically preferred shares. This conversion aims to enhance the company's financial standing by eliminating a shareholder deficit and improving compliance with Nasdaq listing requirements. However, the implementation is contingent on formal approvals and amendments to corporate governance documents. As a result, the company's long-term liabilities could be substantially reduced, benefiting shareholders.
Read more →SCNIScinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
Scinai Immunotherapeutics Ltd. received an extension from the Nasdaq Hearings Panel, allowing it until August 14, 2024, to regain compliance with stockholders' equity requirements. This follows a determination that the company did not meet Nasdaq's minimum equity standards. At a prior hearing, Scinai proposed a plan to convert debt to equity to address its deficiencies. Despite this extension, there is no assurance that the company will be able to fulfill the imposed conditions and maintain its listing status.
Read more →SCNIScinai Publishes Q1 2024 Financial Results and Provides Business Update
Scinai Immunotherapeutics Ltd. reported its financial results for Q1 2024, highlighting a strategic pivot supported by raising $1.69 million. The company regained compliance with Nasdaq's minimum bid price requirement but continues to face challenges with non-compliance in equity. For 2024, Scinai maintains an optimistic sales guidance of $1.25 million. Among its developments, the company is advancing preclinical work on its NanoAb therapeutic for plaque psoriasis, which has shown promising results in animal studies.
Read more →SCNI▲ +23.8%on this news· ran to +99% by day 1
CLICK TO EDIT MASTER TITLE STYLE CORPORATE PRESENTATION | JUNE 2024 | NASDAQ: SCNI NON - CONFIDENTIAL PUBLIC INFORMATION CLICK TO EDIT MASTER TITLE STYLE 2 SAFE HARBOR STATEMENT This communication contains forward - look
Scinai Immunotherapeutics Ltd. has released a corporate presentation outlining its strategic direction, including advancements in its pipeline of nanosized antibodies (NanoAbs). The company discusses its recent collaborations with prominent institutions and ongoing studies for potential treatments in psoriasis and COVID-19. However, Scinai also highlights the inherent risks involved in drug development and the uncertainties regarding its market potential and financial stability. The presentation reflects both progress and the challenges facing the company's future ventures.
Read more →SCNIScinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity
Scinai Immunotherapeutics has received a non-binding Letter of Intent from the European Investment Bank, detailing terms for converting approximately $27.6 million in loans to equity. This conversion is expected to significantly improve the company’s financial position by eliminating a shareholder deficit and creating a substantial equity surplus. The successful implementation of these terms is contingent upon formal approvals from the EIB, with potential risks regarding compliance with Nasdaq listing requirements persisting. The management is optimistic about the potential positive impacts on their operations in the inflammation and immunology sector.
Read more →SCNI▼ -28.4%on this news
Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders
Scinai Immunotherapeutics Ltd. has announced that it regained compliance with Nasdaq's minimum bid price requirement after adjusting the ADS ratio. The company plans to convert a significant portion of its loan with the European Investment Bank into equity to address ongoing compliance issues. Although progress is being made, Scinai remains non-compliant with Nasdaq's equity listing requirement, requiring further actions ahead of a scheduled hearing.
Read more →SCNIScinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders'
Scinai Immunotherapeutics Ltd. has successfully regained compliance with Nasdaq's minimum bid price requirement as of June 5, 2024, following a strategic adjustment in the American Depositary Shares (ADS) ratio. The company is in discussions with the European Investment Bank to convert a substantial portion of its loan into equity, which is integral to the plan for regaining compliance with Nasdaq's minimum shareholders' equity requirement. A hearing before the Nasdaq Hearings Panel is scheduled for June 18, 2024, regarding this compliance issue, amidst ongoing risks related to the conversion and research developments.
Read more →SCNI▲ +12.5%on this news
Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders
Scinai Immunotherapeutics Ltd. has received a second Nasdaq determination letter regarding noncompliance with minimum shareholders' equity requirements. The Company has requested a hearing to present a plan for regaining compliance, which may involve converting part of a loan from the European Investment Bank into equity. Currently, the firm's American Depositary Shares will trade on Nasdaq while addressing their compliance issues. The company reported a stockholders' deficit significantly below the Nasdaq Capital Market requirements.
Read more →SCNI▼ -10.9%on this news
Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining Compliance JERUSALEM, ISRAEL - May 24th,
Scinai Immunotherapeutics Ltd. received a Nasdaq staff determination letter regarding its noncompliance with the minimum shareholders' equity requirement. The company plans to address this issue at a scheduled hearing on June 18th. Potential strategies include converting part of a loan from the European Investment Bank into equity to comply with Nasdaq rules. Currently, Scinai's American Depositary Shares are set to continue trading pending the outcome of this hearing.
Read more →SCNIScinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update
Scinai Immunotherapeutics Ltd. has published its FY 2023 financial statements and provided a business update, highlighting a strategic pivot and recent financial activities. The company raised $1.69 million and received a grant supporting its CDMO services. Promising results for the NanoAb product line were reported, alongside a decrease in overall expenses. However, the company also faces challenges, reporting a net loss and a significant decline in cash reserves compared to the previous year.
Read more →SCNIScinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal
Scinai Immunotherapeutics Ltd. announced it has received a delisting notification from Nasdaq due to non-compliance with the minimum bid price requirement. To address this issue, the company has appealed the decision and implemented a reverse stock split aimed at regaining compliance. The ratio change is set to take effect on May 21, 2024, and is expected to correct the trading price issue. However, there are risks involved including the uncertainty of the appeal's success and potential financial ramifications.
Read more →SCNIScinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal The Board has Approved a Ratio Change of the ADSs to Non-traded Ordinary Shares (equivalent to a reverse split) Designed to Regain C
Scinai Immunotherapeutics has received a delisting notification from Nasdaq for failing to meet the minimum bid price of $1.00 for its American Depositary Shares (ADSs). In response, the company has appealed the decision and is seeking a hearing to discuss the matter further. Additionally, Scinai's Board has approved a change in the ADS ratio, effectively conducting a reverse split, aimed at regaining compliance before the impending hearing. The ratio change will take effect on May 21, 2024, and is projected to address the price compliance issue. However, there is no guarantee the change will resolve the issue in time, leaving the company's future on Nasdaq uncertain.
Read more →SCNICLICK TO EDIT MASTER TITLE STYLE CORPORATE PRESENTATION | APRIL 2024 | NASDAQ: SCNI NON - CONFIDENTIAL PUBLIC INFORMATION CLICK TO EDIT MASTER TITLE STYLE 2 SAFE HARBOR STATEMENT This communication contains forward - loo
Scinai Immunotherapeutics Ltd. held a corporate presentation outlining its forward-looking strategies and business developments for 2024. The focus is on nanosized antibodies (NanoAbs) and their therapeutic potential, particularly in the fields of inflammation, immunology, and viral infections. The company also highlighted recent advancements, including partnerships and the commencement of clinical trials for treatment options like psoriasis. However, the presentation acknowledged various risks and uncertainties that could impact the realization of these opportunities.
Read more →SCNI▼ -6.6%on this news
CLICK TO EDIT MASTER TITLE STYLE Elevating dermatological drug development through advanced inflammatory marker targeting methodology - Focus of IL - 17 in the pathophysiology of psoriasis and unmet medical need - 5th DD
Recent advancements in dermatological drug development emphasize the targeting of inflammatory markers, particularly IL-17, in the treatment of psoriasis. This systemic, chronic inflammatory disorder impacts a significant portion of the population, often resulting in comorbidities that diminish the quality of life. The presentation highlighted IL-17's role in the pathophysiology of psoriasis, showcasing a focused methodology that promises to address the unmet medical needs in this field. The research underscores the necessity for improved therapeutic targets to better manage the condition.
Read more →SCNIScinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG
Scinai Immunotherapeutics Ltd. plans to present its innovative local therapy for plaque psoriasis at the upcoming Dermatology Drug Development Summit in Berlin. The presentation will focus on the therapeutic potential of Scinai's Anti-IL-17A/F NanoAbs, designed to address significant unmet needs in treating mild to moderate plaque psoriasis. The company's Chief Science Officer will discuss findings from ex-vivo studies and the ongoing in-vivo studies that aim to showcase the effectiveness of this novel treatment. Results from the in-vivo study are expected in May, which could further validate Scinai's therapeutic approach.
Read more →SCNIScinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. has entered into a five-year Master Service Agreement with Ayana Pharma to provide drug development and cGMP manufacturing services. The contract, projected to generate at least $1.8 million in revenue, will include encapsulating drug substances into Ayana's liposomal drug delivery system. Ayana's COO praised Scinai both for its expertise in biopharmaceutical development and for their responsive service. This agreement highlights Scinai's strategic direction in expanding its contract development and manufacturing organization (CDMO) services while fostering collaboration with innovative biotech partners.
Read more →SCNIScinai leadership to attend BIO-Europe Spring 2024
Scinai Immunotherapeutics Ltd. will attend the BIO-Europe Spring 2024 conference in Barcelona from March 18 to 20. The company aims to connect with prospective clients for its CDMO services and explore partnerships related to its NanoAb pipeline, specifically for treating plaque psoriasis. Scinai's leadership will engage in discussions with institutional investors and is set to showcase its services at booth #119. This participation points to Scinai's strategic efforts in advancing its innovative products and growing its business partnerships.
Read more →SCNIScinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) announced its upcoming participation in the MIXiii International Life Science and Health-tech Conference scheduled for March 5 and 6 in Jerusalem. The leadership team will discuss Scinai's biologics contract development and manufacturing organization (CDMO) services and its innovative NanoAb pipeline with potential clients and partners. This event aims to foster collaboration with pharmaceutical companies and attract investor interest as Scinai also prepares for participation in additional international conferences.
Read more →SCNIScinai Welcomes Liat Halpert as Head of Business Development and Sales
Scinai Immunotherapeutics Ltd. has appointed Liat Halpert as the Head of Business Development and Sales, bringing over 14 years of experience from Novartis. Her initial focus will be on expanding Scinai Bioservices, a CDMO unit, to serve biotech companies in Europe and the US. The company is developing nanosized VHH antibodies aimed at treating inflammatory and immunological diseases, with successful preclinical trials reported for its IL-17 NanoAb targeting plaque psoriasis. Halpert's leadership is anticipated to drive further growth and collaboration with larger pharma entities.
Read more →SCNIScinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Görlich on Louis-Jeantet Prize
Scinai Immunotherapeutics congratulates Professor Dirk Görlich on winning the 2024 Louis-Jeantet Prize for his groundbreaking contributions to biomedicine. Görlich is a co-lead researcher at Scinai and plays a crucial role in developing nanosized VHH antibodies, which are central to the company's innovative therapeutic pipeline. Recent ex-vivo studies suggest that Scinai's anti-IL-17 NanoAb could be a promising treatment for plaque psoriasis. The recognition serves to enhance the credibility and visibility of Scinai's research endeavors in inflammation and immunology.
Read more →SCNICLICK TO EDIT MASTER TITLE STYLE CORPORATE PRESENTATION | JANUARY 2024 | NASDAQ: SCNI CLICK TO EDIT MASTER TITLE STYLE 2 SAFE HARBOR STATEMENT This communication contains forward - looking statements within the meaning o
Scinai Immunotherapeutics Ltd. has provided a comprehensive corporate presentation outlining its forward-looking strategies and future developments for 2024. The company is focusing on its pipeline of nanosized antibodies (NanoAbs) targeting various medical conditions including psoriasis and COVID-19. However, it acknowledges potential risks and uncertainties that could affect the realization of their therapeutic potential and financial goals. New developments also include the launch of its CDMO services, aimed at enhancing drug development capabilities.
Read more →SCNIScinai Immunotherapeutics CEO Issues Letter to Shareholders
Scinai Immunotherapeutics Ltd. published a letter from CEO Amir Reichman detailing the company's achievements in 2023 and outlining plans for 2024. The highlights include promising preclinical trial results for their anti-IL-17 NanoAb psoriasis therapy, which addresses significant unmet needs in treatment options. The CEO also announced the launch of the Scinai Bioservices CDMO business unit, aimed at supporting biotech companies while improving Scinai's financial standing through various fundraising efforts. Looking ahead, the company plans to initiate human clinical trials for its therapeutic products early next year.
Read more →SCNIScinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds
Scinai Immunotherapeutics Ltd. has announced the closure of a warrant exercise that generated approximately $1.69 million in gross proceeds. The exercise involved warrants to purchase up to 2,606,552 American Depositary Shares at a significantly reduced price. Funds from this transaction are earmarked for general working capital, research, and development. Additionally, the company issued new unregistered warrants to help secure future funding.
Read more →SCNI▼ -14.9%on this newsshared move
Scinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds
Scinai Immunotherapeutics Ltd. announced the immediate exercise of outstanding warrants, resulting in approximately $1.69 million in gross proceeds. The warrants will facilitate Scinai's objectives in research, development, and working capital. Additionally, the company will issue new warrants as part of the agreement, further positioning itself for future growth. Closing of the offering is anticipated by January 3, 2024, pending customary closing conditions.
Read more →SCNI▲ +9.4%on this newsshared move
Scinai (NASDAQ: SCNI) to Host Analyst and Investor Webinar on January 9
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has announced a webinar scheduled for January 9, 2024, where CEO Amir Reichman will present the company's accomplishments for 2023 and plans for 2024. Key highlights will include the anticipated entry of Scinai's anti-IL-17 VHH antibody treatment for psoriasis into clinical trials by the end of this year. The event will offer an opportunity for analysts and investors to engage with the management and ask questions about the company's strategic direction and product pipeline.
Read more →SCNI▼ -5.7%on this news
Scinai Announces Promising Results in a Psoriatic Human Skin Model
Scinai Immunotherapeutics announced promising preclinical results for its anti-IL-17 NanoAbs as a treatment for mild to moderate plaque psoriasis. Conducted by Genoskin, the study demonstrated significant anti-inflammatory effects and improved skin viability compared to standard treatments like Cosentyx and Betamethasone. The results suggest that Scinai's NanoAbs could offer a safe and effective local treatment option for a largely underserved patient population. Future plans include in-vivo animal studies in collaboration with the Technion Israel Institute before initiating human trials in late 2024.
Read more →SCNIStudy published in Antiviral Research supports promise of Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. has announced the publication of a study in Antiviral Research showcasing the effectiveness of its aerosolized NanoAbs in neutralizing SARS-CoV-2. This novel treatment, developed in collaboration with prominent research institutes, displays significant potential in reducing virus load and pathogenicity in animal models. The publication is a key milestone for Scinai, reflecting their innovative approach to address viral infections and underlining their ongoing development efforts, including future projects targeting autoimmune diseases.
Read more →SCNI▲ +7.1%on this news· ran to +17% by day 3
European Investment Bank (EIB) extends maturity of its finance facility with Scinai Immunotherapeutics from 2027 to 2031
Scinai Immunotherapeutics announced an extension of its finance contract with the European Investment Bank, extending the maturity date to December 31, 2031. This amendment is expected to positively impact Scinai's financial health and aligns with its strategy to develop innovative nanosized antibody therapeutics for autoimmune diseases. Scinai's CEO expressed gratitude for the EIB's support, emphasizing the importance of adequate resources and time to achieve business goals. The extension also forms part of the basis for Scinai's compliance with Nasdaq's equity requirement.
Read more →SCNI▼ -6.3%on this news
Scinai Immunotherapeutics Regains Compliance with Nasdaq
Scinai Immunotherapeutics Ltd. has announced that it has regained compliance with Nasdaq listing rules concerning minimum stockholders' equity. This follows the company's submission of a revised financial facility contract with the European Investment Bank and a change in the functional currency to USD to align with its new business strategy. Despite this positive development, Scinai faces ongoing challenges, including a warning about its minimum bid price compliance, which it must address to avoid delisting issues in the future.
Read more →SCNIScinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit
Scinai Immunotherapeutics has received a non-dilutive grant from the Israel Innovation Authority to support its new CDMO business unit. The grant, amounting to approximately $900,000, will cover 66% of project costs aimed at enhancing Scinai's manufacturing capabilities. This funding will help position Scinai as a key player in the biopharmaceutical manufacturing sector.
Read more →SCNIScinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance
Scinai Immunotherapeutics Ltd. received a Nasdaq compliance letter indicating non-compliance with the minimum bid price requirement. The company has 180 days to regain compliance. Additionally, Scinai's primary creditor, the European Investment Bank, is considering adjusting the terms of its financial facility, which could positively impact shareholders' equity. However, there are no guarantees regarding these adjustments.
Read more →SCNIEuropean Investment Bank (EIB) considering extending maturity of its financial facility contract with Scinai Immunotherapeutics in light of Scinai’s recent strategic pivot
Scinai Immunotherapeutics is in discussions with the European Investment Bank (EIB) regarding a potential extension of the maturity of its financial facility contract. This adjustment could positively impact Scinai's financial position and help restore compliance with Nasdaq Listing Rules. The EIB's decision is expected by November 2023.
Read more →SCNIScinai Reports Third Quarter 2023 Financial Results and Provides Business Update
Scinai Immunotherapeutics Ltd. reported its financial results for Q3 2023, showing a significant decrease in cash reserves and an operating loss of $7.8 million. The company is focusing on developing innovative biological products and has launched a new CDMO business unit. Despite these developments, there are notable risks regarding its financial stability and compliance with Nasdaq regulations.
Read more →SCNIScinai Immunotherapeutics to Attend BIO-Europe Munich 2023
Scinai Immunotherapeutics will showcase its CDMO services and VHH antibody therapies at BIO-Europe Munich 2023. The company aims to establish partnerships while highlighting its capabilities in biologics manufacturing and innovative treatments for autoimmune and infectious diseases. The event will take place from November 6 to 8, 2023.
Read more →SCNI▼ -6.1%on this news· ran to -18% by day 3
Scinai Immunotherapeutics to Showcase its end-to-end cGMP Biologics CDMO Services at CPHI Barcelona 2023
Scinai Immunotherapeutics Ltd. will showcase its end-to-end cGMP biologics CDMO services at CPHI Barcelona from October 24 to 26. The company's executive team will meet with potential partners at their booth. Scinai also plans to attend other events in Europe, highlighting its commitment to expanding its CDMO offerings and product pipeline.
Read more →SCNIY ea s t: P i chi a pas t or i s IL - 17 is a cytokine that plays a key role in the development of psoriatic lesions, which are in essence an acute, local (dermis) flareup of a chronic underlying disease . It allows for
The article discusses the role of IL-17, a cytokine, in the formation of psoriatic lesions, highlighting its significance in the inflammatory process associated with psoriasis. It points out the potential for local administration of anti-IL-17 therapies, which may offer a targeted approach to managing this chronic condition. Additionally, the presence of Psoriasin in skin models indicates its relevance to understanding skin inflammation.
Read more →SCNIScinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering
Scinai Immunotherapeutics Ltd. has successfully closed a registered direct offering, raising approximately $1.33 million through the sale of 1,146,552 American Depositary Shares at $1.16 each. The company plans to use the proceeds for general working capital and research and development. The offering included unregistered warrants that are immediately exercisable.
Read more →SCNI▼ -15.5%on this newsshared move
Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering
Scinai Immunotherapeutics Ltd. announced a definitive agreement for a registered direct offering of over 1.14 million American Depositary Shares at $1.16 each, aiming to raise approximately $1.33 million. The proceeds from this offering will primarily support general working capital and research and development initiatives. The transaction, facilitated by H.C. Wainwright & Co., is expected to close around September 19, 2023, pending customary closing conditions. Despite the positive outlook on funding, the company acknowledges several risks regarding market conditions and regulatory approvals.
Read more →SCNI▼ -11.5%on this news· ran to -26% by day 3shared move
Scinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows Encouraging Preclinical Results
Scinai Immunotherapeutics has reported promising preclinical results for its NanoAbs targeting plaque psoriasis. The study demonstrated the downregulation of key psoriasis markers and restoration of normal skin appearance in a 3D model. Future studies in human skin and animal models are anticipated, with the potential for a safer treatment option for mild to moderate psoriasis patients.
Read more →SCNIScinai Immunotherapeutics Ltd. to participate this week in H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in Boston
Scinai Immunotherapeutics Ltd. announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference in New York and the LSX USA Congress 2023 in Boston. CEO Amir Reichman and Chairman Mark Germain will represent the company, inviting investors for meetings. Scinai is focused on developing innovative treatments for autoimmune and infectious diseases.
Read more →SCNIY ea s t: P i chi a pas t or i s " - - - - 10 1 10 2 10 3 10 4 10 5 10 6 Titer [TCID 50 /g] limit of detection 9 8 7 6 5 4 3 2 1 SARS - CoV - 2 RNA copies/ml BALF de t e c t i o n limit
The article presents data related to yeast, specifically Pichia pastoris, and mentions various titer measurements and detection limits for SARS-CoV-2 RNA copies in bronchoalveolar lavage fluid. It provides specific quantitative data relevant to the detection capabilities. However, the context and implications of this data are not extensively elaborated upon in the text provided.
Read more →SCNIYeast: Pichia pastoris " - - - - 10 1 10 2 10 3 10 4 10 5 10 6 Titer [TCID 50 /g] limit of detection 9 8 7 6 5 4 3 2 1 SARS - CoV - 2 RNA copies/ml BALF detection limit
The article discusses the performance of the yeast Pichia pastoris in relation to SARS-CoV-2, presenting data on titer levels and detection limits. Specifically, it outlines the limits of detection for SARS-CoV-2 RNA copies per milliliter in bronchoalveolar lavage fluid (BALF). The numerical data presented includes various titer levels, indicating the yeast's potential applications. However, the lack of context or detailed analysis leaves the implications of these findings unclear.
Read more →SCNIBiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics Scinai Immunotherapeutics to debut tomorrow
BiondVax Pharmaceuticals Ltd. has officially rebranded as Scinai Immunotherapeutics Ltd., reflecting its new focus on the development of novel inflammation and immunology biological therapeutics. The company, which will start trading under the ticker SCNI, aims to leverage advanced NanoAbs to create improved therapeutics. Scinai has established partnerships with prestigious institutions, enhancing its research capabilities while also launching a CDMO business unit. Although optimistic about its growth potential, Scinai faces challenges typical of the biotech sector, including securing necessary funding.
Read more →SCNIN o n c o n f i d e n t i al p r e s e n t at i o n | A u g u s t 22, 2023 This communication contains forward - looking statements within the meaning of the Private Litigation Reform Act of 1995 . Words such as "expect,
BiondVax Pharmaceuticals has provided a forward-looking presentation detailing its strategic plans, particularly focusing on the potential of its nanobody technology and the capabilities of its Contract Development and Manufacturing Organization (CDMO). The presentation highlighted the management's confidence in their products, backed by a seasoned leadership team with extensive experience in the biotech sector. However, the company also acknowledged several risks that could impact their projections, including regulatory challenges and market competition.
Read more →SCNIBIONDVAX PHARMACEUTICALS LTD. FINANCIAL STATEMENTS AS OF JUNE 30, 2023 U.S. DOLLARS IN THOUSANDS Unaudited INDEX Page Condensed Balance Sheets 2 - 3 Condensed Statements of Operations 4 Condensed Statements of Comprehens
BiondVax Pharmaceuticals Ltd. released its unaudited financial statements for the period ending June 30, 2023. The report indicates a significant decline in total assets and an increase in net loss compared to the previous year. Cash reserves have also decreased notably, raising concerns about the company's financial sustainability. The financial outlook appears challenging, given the growing losses and reduced liquidity.
Read more →SCNIBiondVax Reports Second Quarter Financial Results and Provides Business Update Jerusalem, Israel
BiondVax Pharmaceuticals Ltd. announced its financial results for the second quarter ended June 30, 2023, revealing an operating loss of $7.3 million and cash equivalents decreasing to $7.6 million. The company has initiated a cost-savings plan that includes reducing headcount and postponing non-essential expenditures. Despite these challenges, BiondVax continues to focus on developing its immunotherapeutic products and has begun actions to seek additional capital to sustain operations. Management believes that existing resources may meet liquidity needs for the next twelve months, although this is not guaranteed.
Read more →SCNINasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules Jerusalem, Israel
BiondVax Pharmaceuticals Ltd. has received a deadline extension from Nasdaq until October 30, 2023, to demonstrate compliance with the stockholders' equity requirement for continued listing. In response, the company is implementing a multifaceted plan which includes the pursuit of a strategic partnership for its COVID-19 therapy and plans to launch a new contract manufacturing unit. The CEO expressed confidence in the company's ability to regain compliance and highlighted the expected demand for their CDMO services. Failure to comply may result in delisting, yet BiondVax could appeal such a decision.
Read more →SCNIBIONDVAX PHARMACEUTICALS LTD. Jerusalem BioPark, 2 nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held on
BiondVax Pharmaceuticals Ltd. has announced its Annual General Meeting of Shareholders scheduled for August 24, 2023, at the offices of Goldfarb Gross Seligman & Co. in Tel Aviv, Israel. Shareholders will review the company's financial performance for the year ended December 31, 2022, and vote on various proposals. The meeting is set to be held at 4:00 p.m. Israel time, with specific voting processes and proxy voting procedures outlined for participants. The company emphasizes the importance of shareholder participation, either in person or through proxies.
Read more →SCNINASDAQ: BVXV | July 2023 2 This communication is not a prospectus or offer of securities for subscription or sale in any jurisdiction. This communication contains forward - looking statements within the meaning of the Pr
BiondVax Pharmaceuticals is advancing its innovative VHH antibody (NanoAb) platform, targeting significant unmet medical needs within large commercial markets. Their efforts, supported by collaboration with the Max Planck Institute, focus on developing treatments for conditions such as psoriasis, asthma, and COVID-19. However, the company faces several risks, including potential delays in clinical data and the necessity to acquire further funding and partnerships. Management's statements indicate a positive outlook on commercial opportunities while acknowledging substantial uncertainties ahead.
Read more →SCNINASDAQ: BVXV | May 2023 2 This communication is not a prospectus or offer of securities for subscription or sale in any jurisdiction. This communication contains forward - looking statements within the meaning of the Pri
BiondVax Pharmaceuticals Ltd. is making strides in developing nanosized antibodies (NanoAbs), targeting various diseases including asthma and psoriasis, through a collaboration with the Max Planck Institute. The company emphasizes the advantages of its NanoAb platform, which promises quicker and more efficient therapeutic development. However, uncertainties remain regarding the company's ability to capitalize on these advancements, including potential delays in clinical trials and securing additional funding. Regulatory approval for its manufacturing facility in Jerusalem is also a critical factor for future progress.
Read more →SCNIBiondVax's Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study COVID-19 illness was virtually prevented in hamsters administered BiondVax'
BiondVax Pharmaceuticals has announced promising results from a preclinical study of its inhaled NanoAb for COVID-19. In trials, hamsters receiving the NanoAb prophylactically showed no significant weight loss, while untreated controls lost an average of 12%. The NanoAb has the potential to serve as both a preventive and therapeutic agent, addressing a growing demand for COVID prophylactics. Following these results, BiondVax plans to advance to a first-in-human clinical trial later this year.
Read more →SCNIAMIR REICHMAN, CEO BIOTECH SHOWCASE | JANUARY 2023 2 This communication is not a prospectus or offer of securities for subscription or sale in any jurisdiction. This communication contains forward - looking statements wi
BiondVax Pharmaceuticals is promoting its nanosized antibody (NanoAb) technology, claiming significant potential in treating COVID-19 and other diseases. The company has reported promising preclinical results demonstrating the efficacy of inhaled NanoAbs against various COVID-19 variants. Collaborative efforts with the Max Planck Institute and UMG are expected to bolster the development and commercialization of these therapeutics. However, uncertainties remain regarding the timeline and success of clinical trials, posing risk to the projected market potential.
Read more →SCNIBiondVax's Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study Hamsters infected with SARS-COV-2 and then treated with BiondVax's inhaled anti-COVID-19 nanosized antibod
BiondVax Pharmaceuticals has announced promising preclinical results from its inhaled COVID-19 therapy, which utilizes nanosized antibodies to virtually eliminate the SARS-CoV-2 virus in infected hamsters. The study demonstrated a significant reduction in viral presence in the lungs of treated animals compared to a placebo group. Additionally, the hamsters that received the treatment experienced less weight loss and milder symptoms. These findings pave the way for further studies, including a planned first-in-human clinical trial later in 2023.
Read more →SCNIBiondVax CEO Issues Letter to Shareholders Jerusalem, Israel
BiondVax CEO Issues Letter to Shareholders Jerusalem, Israel - December 30, 2022 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products for the treatment of infectio
Read more →SCNINASDAQ: BVXV | JANUARY 2023 2 This communication is not a prospectus or offer of securities for subscription or sale in any jurisdiction. This communication contains forward - looking statements within the meaning of the
NASDAQ: BVXV | JANUARY 2023 2 This communication is not a prospectus or offer of securities for subscription or sale in any jurisdiction. This communication contains forward - looking statements within the meaning of the Private Litigation Reform Act of 1995 . Words such as "exp
Read more →SCNIBiondVax Announces Closing of $8 Million Underwritten Public Offering JERUSALEM
Announces Closing of $8 Million Underwritten Public Offering Dec. 20, 2022 (GLOBE NEWSWIRE) -- via InvestorWire - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV)("Company"), a biotechnology company, which focuses on developing, manufacturing, and commercializing innovative immunot
Read more →SCNIBiondVax Announces Pricing of $8 Million Underwritten Public Offering JERUSALEM
Pricing of $8 Million Underwritten Public Offering 2022 (GLOBE NEWSWIRE) -- via InvestorWire - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ("Company"), which focuses on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treat
Read more →SCNIBiondVax Regains Nasdaq Compliance Jerusalem
BiondVax Regains Nasdaq Compliance Dec. 12, 2022 (GLOBE NEWSWIRE) -- via InvestorWire - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatm
Read more →SCNIBiondVax announces Third Quarter 2022 Financial Results and Provides Business Update Jerusalem, Israel
announces Third Quarter 2022 Financial Results and Provides Business Update Israel - November 30, 2022 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), which focuses on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatme
Read more →SCNIBiondVax reports successful results in preclinical in vivo study of its innovative inhaled COVID-19 NanoAb therapy Hamsters infected with SARS-COV-2 and then treated with inhaled anti-COVID-19 NanoAbs demonstrated signif
BiondVax reports successful results in preclinical in vivo study of its innovative inhaled COVID-19 NanoAb therapy - November 29, 2022 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing and commercializing
Read more →SCNIBIONDVAX PHARMACEUTICALS LTD. Jerusalem BioPark, 2 nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To Be Held on December 13, 2022 The Extraordinary Gen
BIONDVAX PHARMACEUTICALS LTD. Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To Be Held on December 13, 2022 The Extraordinary General Meeting of Shareholders of BiondVax Pharmaceuticals Ltd. (the Company ) will
Read more →SCNIRAFT meeting | 6 - 9 NOVEMBER 2022 Dalit Weinstein - Fischer 2 This communication is not a prospectus or offer of securities for subscription or sale in any jurisdiction. This communication contains forward - looking sta
1 RAFT meeting | 6 - 9 NOVEMBER 2022 Dalit Weinstein - Fischer 2 This communication is not a prospectus or offer of securities for subscription or sale in any jurisdiction. This communication contains forward - looking statements within the meaning of the Private Litigation Refo
Read more →SCNIBIONDVAX PHARMACEUTICALS LTD. Jerusalem BioPark, 2 nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To Be Held on
BIONDVAX PHARMACEUTICALS LTD. Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To Be Held on December 13, 2022 The Extraordinary General Meeting of Shareholders of BiondVax Pharmaceuticals Ltd. (the "Company") wi
Read more →SCNIBiondVax announces financial plans to support its ongoing NanoAb pipeline development Jerusalem, Israel
BiondVax announces financial plans to support its ongoing NanoAb pipeline development Jerusalem, Israel - September 30, 2022 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovati
Read more →SCNIBiondVax's Strategic Research Collaboration with Max Planck and UMG: Significant progress towards development of innovative nanosized antibodies (NanoAbs) for therapeutic indications in addition to COVID-19 Jerusalem, Is
BiondVax's Strategic Research Collaboration with Max Planck and UMG: Significant progress towards development of innovative nanosized antibodies (NanoAbs) for therapeutic indications in addition to COVID-19 Jerusalem, Israel - September 20, 2022 - BiondVax Pharmaceuticals L
Read more →SCNIBiondVax announces Second Quarter 2022 Financial Results and Provides Business Update JERUSALEM
BiondVax announces Second Quarter 2022 Financial Results and Provides Business Update JERUSALEM, Aug. 25, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), which focuses on developing, manufacturing and commercializing innovative products for the prevention an
Read more →SCNIBiondVax and European Investment Bank sign definitive amendment extending maturity of loan until December 2027 with additional terms in support of BiondVax's new strategy JERUSALEM
BiondVax and European Investment Bank sign definitive amendment extending maturity of loan until December 2027 with additional terms in support of BiondVax's new strategy 10, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused
Read more →SCNIBiondVax receives supportive Scientific Advice from the Paul Ehrlich Institute (PEI) for COVID-19 NanoAb development plans including first-in-human Phase 1/2a safety and efficacy clinical trial PEI supports BiondVax's pl
BiondVax receives supportive Scientific Advice from the Paul Ehrlich Institute (PEI) for COVID-19 NanoAb development plans including first-in-human Phase 1/2a safety and efficacy clinical Jerusalem, Israel - June 7, 2022 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biop
Read more →SCNIBiondVax Announces First Quarter 2022 Financial Results and Provides Business Update Jerusalem, Israel
Announces First Quarter 2022 Financial Results and Provides Business Update Israel - June 1, 2022 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceuticals company focused on developing, manufacturing and commercializing innovative products for the prevention and tre
Read more →SCNIAnalyst and Investor Webinar|
Analyst and Investor Webinar| April 4, 2022 2 This communication is not a prospectus or offer of securities for subscription or sale in any jurisdiction. This communication contains forward - looking statements within the meaning of the Private Litigation Reform Act of 1995 . Wo
Read more →SCNIN A S D A Q : B V X V | J a n u a r y 202 2 2 This communication contains forward - looking statements within the meaning of the Private Litigation Reform Act of 1995 . Words such as "expect," "believe," "intend," "plan,
N A S D A Q : B V X V | J a n u a r y 202 2 2 This communication contains forward - looking statements within the meaning of the Private Litigation Reform Act of 1995 . Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expr
Read more →SCNIBIONDVAX PHARMACEUTICALS LTD. INTERIM FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2021 NIS IN THOUSANDS UNAUDITED INDEX Page Balance Sheets F-2 - F-3 Statements of Comprehensive Loss F-4 Statements of Changes in Shareholder
BIONDVAX PHARMACEUTICALS LTD. INTERIM FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2021 Page Balance Sheets F-2 - F-3 Statements of Comprehensive Loss F-4 Statements of Changes in Shareholders' Equity (Deficiency) F-5 - F-7 Statements of Cash Flows F-8- F-9 Notes to Interim
Read more →SCNIBiondVax Announces Pricing of $9.0 million Follow-on Underwritten Offering of American Depositary Shares Jerusalem, Israel
BiondVax Announces Pricing of $9.0 million Follow-on Underwritten Offering of American Depositary Shares Jerusalem, Israel - December 27, 2021 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing
Read more →SCNIFormer CFO of GSK's Global Vaccines Business Mr. Jay Green Joins BiondVax's Board of Directors Jerusalem, Israel
Former CFO of GSK's Global Vaccines Business Mr. Jay Green Joins BiondVax's Board of Directors Jerusalem, Israel - December 27, 2021 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative
Read more →SCNIBiondVax signs definitive agreements for development and commercialization of innovative nanosized COVID-19 antibody therapy with Max Planck Institute of Biophysical Chemistry and University Medical Center G ttingen, Ger
BiondVax signs definitive agreements for development and commercialization of innovative nanosized COVID-19 antibody therapy with Max Planck Institute of Biophysical Chemistry and University Medical Center G ttingen, Germany Jerusalem, Israel - December 22, 2021 - BiondVax Ph
Read more →SCNIAMIR REICHMAN, CEO NASDAQ: BVXV | DECEMBER 2021 2 This communication is not a prospectus or offer of securities for subscription or sale in any jurisdiction. This communication contains forward - looking statements withi
AMIR REICHMAN, CEO NASDAQ: BVXV | DECEMBER 2021 2 This communication is not a prospectus or offer of securities for subscription or sale in any jurisdiction. This communication contains forward - looking statements within the meaning of the Private Litigation Reform Act of 1995
Read more →SCNIBiondVax announces Third Quarter 2021 Financial Results and Provides Business Update Jerusalem, Israel
BiondVax announces Third Quarter 2021 Financial Results and Provides Business Update Jerusalem, Israel - November 30, 2021 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), which focuses on developing, manufacturing and commercializing innovative products for the prevention and
Read more →SCNIBiondVax Announces Notice of Annual General Meeting of Shareholders and Provides a Business Update Jerusalem, Israel
Notice of Annual General Meeting of Shareholders and Provides a Business Update Jerusalem, Israel - November 24, 2021 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), which focuses on developing, manufacturing and commercializing innovative products for the prevention and treat
Read more →SCNIBiondVax advances its growth strategy towards a new pipeline based on innovative VHH antibodies Signs term sheet for a broad-based strategic collaboration with Max Planck Society and University Medical Center G ttingen,
BiondVax advances its growth strategy towards a new pipeline based on innovative VHH antibodies Signs term sheet for a broad-based strategic collaboration with Max Planck Society and University Medical Center G ttingen, Germany Jerusalem, Israel - October 19, 2021 - BiondVax
Read more →SCNIBiondVax Announces Second Quarter 2021 Financial Results and Provides Business Update Jerusalem, Israel
BiondVax Announces Second Quarter 2021 Financial Results and Provides Business Update Jerusalem, Israel - August 26, 2021 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products f
Read more →SCNIBiondVax Announces First Quarter 2021 Financial Results and Provides Business Update Jerusalem, Israel
BiondVax Announces First Quarter 2021 Financial Results and Provides Business Update Jerusalem, Israel - June 23, 2021 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for
Read more →SCNIBiondVax Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Jerusalem, Israel
Announces Fourth Quarter and Full Year 2020 Financial Results Provides Business Update Israel - May 13, 2021 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevent
Read more →SCNILETTER TO SHAREHOLDERS Letter from BiondVax's New CEO to Shareholders
Letter from BiondVax's New CEO If successfully implemented, this strategy would provide BiondVax with a robust and diverse multi-dimensional pipeline. Over these past few months, we have been actively engaged in identifying and evaluating many opportunities. These include in-l
Read more →SCNIBiondVax Pharmaceuticals Ltd Company Presentation BiondVax Pharmaceuticals Ltd. | Jerusalem, Israel | www.biondvax.com www.biondvax.com March 2021 S AFE H ARBOR S TATEMENT This presentation is not a prospectus or offer o
BiondVax Pharmaceuticals Ltd Company Presentation BiondVax Pharmaceuticals Ltd. | Jerusalem, Israel | www.biondvax.com www.biondvax.com March 2021 S AFE H ARBOR S TATEMENT This presentation is not a prospectus or offer of securities for subscription or sale in any jurisdiction.
Read more →SCNIBIONDVAX PHARMACEUTICALS LTD. Jerusalem BioPark, 2 nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel NOTICE OF EXTRAORDINARY MEETING OF SHAREHOLDERS To Be Held on
BIONDVAX PHARMACEUTICALS LTD. Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus NOTICE OF EXTRAORDINARY MEETING OF SHAREHOLDERS To Be Held on April 6, 2021 An Extraordinary Meeting of Shareholders of BiondVax Pharmaceuticals Ltd. (the "Company") will be held at the off
Read more →SCNIBiondVax Announces Exercise in Full of Underwriter's Over-Allotment Option in Follow-on Offering Total Gross Proceeds of Underwritten Offering Approximately $13.8 million Jerusalem, Israel
BiondVax Announces Exercise in Full of Underwriter's Over-Allotment Option in Follow-on Offering Total Gross Proceeds of Underwritten Offering Approximately $13.8 million Jerusalem, Israel - February 10, 2021 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutica
Read more →SCNIBiondVax Announces Closing of $12.1 Million Follow-on Underwritten Offering Jerusalem, Israel
Announces Closing of $12.1 Million Follow-on Underwritten Offering Israel - February 2, 2021 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment
Read more →SCNIBiondVax Announces Pricing of $12.1 Million Follow-on Underwritten Offering of American Depositary Shares Jerusalem, Israel
Announces Pricing of $12.1 Million Follow-on Underwritten Offering of American Depositary Shares Jerusalem, Israel - January 29, 2021 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing
Read more →SCNIBiondVax Announces Launch of Proposed Underwritten Follow-on Offering of American Depositary Shares Jerusalem, Israel
BiondVax Announces Launch of Proposed Underwritten Follow-on Offering of American Depositary Shares Jerusalem, Israel - January 28, 2021 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commerciali
Read more →SCNIBiondVax Announces Third Quarter 2020 Financial Results & Business Update Jerusalem, Israel
BiondVax Announces Third Quarter 2020 Financial Results & Business Update Jerusalem, Israel - January 28, 2021 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prev
Read more →SCNIBiondVax Announces Appointment of Amir Reichman as New CEO Pharma Industry Veteran in Vaccines will Assume Role Full Time
Announces Appointment of Amir Reichman as New CEO Veteran in Vaccines will Assume Role Full Time March 2, 2021 on Developing Product Pipeline in Infectious Diseases Jerusalem, Israel - January 21, 2021 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical compan
Read more →SCNIBiondVax Announces Topline Results from Phase 3 Clinical Trial of the M-001 Universal Influenza Vaccine Candidate Jerusalem, Israel
BiondVax Announces Topline Results from Phase 3 Clinical Trial of the M-001 Universal Influenza Vaccine Candidate Jerusalem, Israel - October 23, 2020 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a pioneer in the development of a universal flu vaccine designed to provide p
Read more →SCNIBiondVax Announces At-The-Market (ATM) Equity Offering Program Jerusalem, Israel
BiondVax Announces At-The-Market (ATM) Equity Offering Program Jerusalem, Israel - October 2, 2020 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the Phase 3 clinical trial M-001 universal influenza vaccine candidate ("BiondVax" or the "Company"), today announce
Read more →SCNIBIONDVAX PHARMACEUTICALS LTD. CONDENSED INTERIM FINANCIAL STATEMENTS AS OF JUNE 30, 2020 NIS IN THOUSANDS UNAUDITED INDEX Page Condensed Interim Balance Sheets F-2 - F-3 Condensed Interim Statements of Comprehensive Loss
PHARMACEUTICALS LTD. INTERIM FINANCIAL STATEMENTS Page Condensed Interim Balance Sheets F-2 - F-3 Condensed Interim Statements of Comprehensive Loss F-4 Condensed Interim Statements of Changes in Shareholders' Deficiency F-5 - F-7 Condensed Interim Statements of Cash Flows F-8
Read more →SCNITHE NEW PARADIGM : THE UNIVERSAL FLU VACCINE September 2020 2 This presentation is not a prospectus or offer of securities for subscription or sale in any jurisdiction . All statements in this communication, other than t
THE NEW PARADIGM : THE UNIVERSAL FLU VACCINE September 2020 2 This presentation is not a prospectus or offer of securities for subscription or sale in any jurisdiction . All statements in this communication, other than those relating to historical facts, are "forward - looking s
Read more →SCNIBiondVax Announces Second Quarter 2020 Financial Results Jerusalem, Israel
Announces Second Quarter 2020 Financial Results Israel - August 20, 2020 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal influenza vaccine candidate, today announced its seco
Read more →SCNIBiondVax Announces Notice of Annual General Meeting of Shareholders and Provides a Clinical Trial Update Jerusalem, Israel
BiondVax Announces Notice of Annual General Meeting of Shareholders and Provides a Clinical Trial Update Jerusalem, Israel - August 13, 2020 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the Phase 3 clinical trial M-001 universal influenza vaccine candidate, to
Read more →SCNILast of 12,400 Participants Completes Final Visit in BiondVax's M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial Jerusalem, Israel
Last of 12,400 Participants Completes Final Visit in BiondVax's M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial Jerusalem, Israel - July 1, 2020 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) today announced that all participants in the placebo-controlled, blinded,
Read more →SCNIBiondVax Announces First Quarter 2020 Financial Results Jerusalem, Israel
First Quarter 2020 Financial Results Jerusalem, Israel - June 30, 2020 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal influenza vaccine candidate, today announced its first
Read more →SCNIBiondVax Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update Jerusalem, Israel
BiondVax Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update Jerusalem, Israel - June 12, 2020 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a
Read more →SCNINIH Report on Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Concludes Both Primary Endpoints Achieved Jerusalem, Israel
NIH Report on Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Concludes Both Primary Endpoints Achieved Jerusalem, Israel - June 10, 2020 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) today announced the completion of the clinical study repor
Read more →SCNIBiondVax Announces Receipt of $4.2 million through Exercise of Warrants Jerusalem, Israel
BiondVax Announces Receipt of $4.2 million through Exercise of Warrants Jerusalem, Israel - May 20, 2020 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the M-001 universal influenza vaccine candidate, today announced receipt of proceeds of approximately $4.2 mil
Read more →SCNIBiondVax Announces Upcoming Expiration of Public Warrants Jerusalem, Israel
Announces Upcoming Expiration of Public Warrants Jerusalem, Israel - May 4, 2020 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the universal influenza vaccine candidate M-001, today published a reminder that its publicly traded warrants (traded on Nasdaq under t
Read more →SCNINew Directors Elected to BiondVax's Board of Directors Jerusalem, Israel
New Directors Elected to BiondVax's Jerusalem, Israel - March 24, 2020 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the universal influenza vaccine candidate M-001, announced that all proposed resolutions were approved at the Company's Annual General Meeting he
Read more →SCNIBiondVax's CEO Comments on Impact of COVID-19 Pandemic on the Company's Ongoing Phase 3 Clinical Trial Jerusalem, Israel
CEO Comments on Impact of COVID-19 Pandemic on the Company's Ongoing Phase 3 Clinical Trial Jerusalem, Israel - March 19, 2020 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) today issued an update regarding the impact of the COVID-19 pandemic on the ongoing pivotal, clinical e
Read more →SCNIPreliminary Data from NIH/NIAID-sponsored Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Validates Results of Previous Clinical Trials Data published on Clinicaltrials.gov Jerusalem, Isr
Preliminary Data from NIH/NIAID-sponsored Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Validates Results of Previous Clinical Trials Data published on Clinicaltrials.gov Jerusalem, Israel - February 5, 2020 - BiondVax Pharmaceuticals Ltd.
Read more →SCNIAMENDMENT NO. 1 TO ADS WARRANT AGENT AGREEMENT This Amendment No.1 to ADS Warrant Agent Agreement (the " Amendment ") is made as of
AMENDMENT NO. 1 TO ADS WARRANT AGENT AGREEMENT to ADS Warrant Agent Agreement (the "Amendment") is made as of January 16, 2020 (the "Amendment Effective Date") by and between BiondVax Pharmaceuticals Ltd. (the "Company") and The Bank of New York Mellon (the "Warrant Agent", an
Read more →SCNIThird Quarter 2019 Financial Results and Business Update
Third Quarter 2019 Financial Results and Business Update Jerusalem, Israel - November 26, 2019 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate,
Read more →SCNIEnrollment and randomization of 12,463 participants complete in BiondVax's pivotal, clinical efficacy, Phase 3 Universal Flu Vaccine trial Results expected by end of 2020 Jerusalem, Israel
Enrollment and randomization of 12,463 participants complete in BiondVax's pivotal, clinical efficacy, Phase 3 Universal Flu Vaccine trial Results expected by end of 2020 Jerusalem, Israel - November 18, 2019 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced today that
Read more →SCNIBiondVax receives 4M from the European Investment Bank (EIB) in support of ongoing Universal Influenza Vaccine Pivotal Phase 3 trial Jerusalem, Israel
BiondVax receives 4M from the European Investment Bank (EIB) in support of ongoing Universal Influenza Vaccine Pivotal Phase 3 trial Jerusalem, Israel - October 7, 2019 -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a phase 3 clinical stage biopharmaceutical company focused
Read more →SCNIWelcomes New Chairman of the Board and Announces
Welcomes New Chairman of the Board and Announces Quarter 2019 Financial Results Israel - August 28, 2019 -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine
Read more →SCNIBiondVax Announces Rights Offering Fully Subscribed at US$20 Million Funds to complete ongoing pivotal, clinical efficacy, Phase 3 trial of the M-001 Universal Flu Vaccine candidate and scale-up manufacturing Jerusalem,
BiondVax Announces Rights Offering Fully Subscribed at US$20 Million Funds to complete ongoing pivotal, clinical efficacy, Phase 3 trial of the M-001 Universal Flu Vaccine candidate and scale-up manufacturing Jerusalem, Israel - July 16, BiondVax Pharmaceuticals Ltd. (Nasd
Read more →SCNIFirst Participant Enrolled in Second Cohort of BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine Trial Jerusalem, Israel
First Participant Enrolled in Second Cohort of BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine Trial Jerusalem, Israel - July 8, BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced today that the first participants in the second cohort of the pivotal,
Read more →SCNIPatent Covering Manufacturing Process of BiondVax's M-001 Universal Flu Vaccine Allowed in USA and Japan Pivotal Clinical Efficacy Phase 3 Clinical Trial Results Expected in 2020 Jerusalem, Israel
Patent Covering Manufacturing Process of BiondVax's M-001 Universal Flu Vaccine Allowed in USA and Japan Pivotal Clinical Efficacy Phase 3 Clinical Trial Results Expected in 2020 Jerusalem, Israel - June BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), announced today that a p
Read more →SCNIBiondVax Announces First Quarter 2019
BiondVax Announces First Quarter 2019 Jerusalem, Israel - May 30, 2019 BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, today announced its financial re
Read more →SCNILetter from BiondVax CEO regarding BiondVax's proposed Rights Offering
from BiondVax CEO regarding BiondVax's proposed Rights Offering Dear BiondVax Shareholder, you are likely aware, BiondVax recently announced its intention to conduct a US$20 million rights offering and, under limited circumstances, a related financing of not more than US$10 mi
Read more →SCNIAnnounces Fourth Quarter and Full Year 2018 Financial Results and Update
Announces Fourth Quarter and Full Year 2018 Financial Results and Update Israel - April 30, 2018 - Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate currently undergoing a pivotal
Read more →SCNIBIONDVAX PHARMACEUTICALS LTD. NOTICE OF AN EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To be held on, 28 th May, 2019 Notice is hereby given that the extraordinary general meeting of shareholders of BiondVax Pharmaceut
PHARMACEUTICALS LTD. OF AN EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS be held on, 28th May, 2019 is hereby given that the extraordinary general meeting of shareholders of BiondVax Pharmaceuticals Ltd. (the "Company"), will be held at the offices of Pearl Cohen Zedek Latzer
Read more →SCNIInvestment Bank (EIB) extends financing agreement to 24 million
Investment Bank (EIB) extends financing agreement to 24 million total in support of BiondVax's universal flu vaccine ongoing pivotal Phase 3 clinical trial million extension to 2017 financing agreement Israel - April 22, 2019 - Pharmaceuticals Ltd. (Nasdaq: BVXV), announced t
Read more →SCNIThe Phase 3 Universal Flu Vaccine J OSHUA P HILLIPSON A PRIL 2 , 2019
The Phase 3 Universal Flu Vaccine J OSHUA P HILLIPSON A PRIL 2 , 2019 This presentation is not a prospectus or offer of securities for subscription or sale in any jurisdiction . All statements in this communication, other than those relating to historical facts, are "forward - l
Read more →SCNILast participant out in USA Phase 2 clinical trial of BiondVax's M-001 Universal Influenza Vaccine candidate Jerusalem, Israel
participant out in USA Phase 2 clinical trial of BiondVax's M-001 Universal Influenza Vaccine candidate Jerusalem, Israel - March 21, BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the M-001 universal influenza vaccine candidate, reported today that all participant
Read more →SCNIQuarter 2018 Financial Results
Quarter 2018 Financial Results Israel - November 13, 2018 -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, today announced its financial result
Read more →SCNIUniversal Flu Vaccine Phase 3 Clinical Trial Completes First Season's Enrollment of 4,098 Participants
Universal Flu Vaccine Phase 3 Clinical Trial Completes First Season's Enrollment of 4,098 Participants Israel, October 24, 2018 -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced today the successful enrollment of the last participant in the first season of a pivotal, cl
Read more →SCNIreceives 8M from the European Investment Bank (EIB) in support of manufacturing facility and ongoing Phase 3 clinical trial
receives 8M from the European Investment Bank (EIB) in support of manufacturing facility and ongoing Phase 3 clinical trial Israel, October 22, 2018 -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of M-001, a clinical phase 3 Universal Influenza Vaccine candidate, an
Read more →SCNISecond Quarter 2018 Financial Results
Second Quarter 2018 Financial Results Jerusalem, Israel - August 22, 2018 -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, today announced its
Read more →SCNIArrangement to Conclude Proceedings, Subject to Conditions in accordance With Section B to Chapter 9A of the Securities Law 5728-1968 That was drawn and entered into on August 13 2018, between the following parties: Stat
to Conclude Proceedings, Subject to Conditions in accordance With Section B to Chapter 9A of the Securities Law 5728-1968 was drawn and entered into on August 13 2018, between the following parties: by the Tel-Aviv District Attorney (Taxation and Economics) Menachem Begin Str
Read more →SCNIBiondVax Moves to New Universal Flu Vaccine Manufacturing Facility State-of-the-art facility designed for annual capacity of 40 million doses in bulk with up to 20 million single dose syringes Jerusalem, Israel
BiondVax Moves to New Universal Flu Vaccine Manufacturing Facility facility designed for annual capacity of 40 million doses in bulk with up to 20 million single dose syringes Jerusalem, Israel - August 20, 2018 BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), developer of the M
Read more →SCNIBiondVax receives second 6M tranche disbursement from the European Investment Bank (EIB)
receives second 6M tranche disbursement the European Investment Bank (EIB) ZIONA, Israel, August 14, 2018 -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of M-001, a clinical phase 3 Universal Influenza Vaccine candidate, announced today the receipt of a 6 million d
Read more →SCNIFirst Participant Enrolled in BiondVax's Universal Flu Vaccine Pivotal Phase 3 Clinical Trial M-001 vaccine designed to protect against current, future, seasonal, and pandemic influenza strains Ness Ziona, Israel
Participant Enrolled in BiondVax's Universal Flu Vaccine Phase 3 Clinical Trial vaccine designed to protect against current, future, seasonal, and pandemic influenza strains Ziona, Israel - August 8, 2018 Pharmaceuticals Ltd. (Nasdaq: BVXV) reported today the first participan
Read more →SCNIBiotech Executive Mark Germain Joins BiondVax's Board of Directors
Biotech Executive Mark Germain Joins BiondVax's Board of Directors ZIONA, Israel, June 28, 2018 -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of M-001, a clinical phase Universal Influenza Vaccine candidate, announced today the appointment of Mr. Mark Germain as Vi
Read more →SCNIreceives its first 6M tranche disbursement
receives its first 6M tranche disbursement the European Investment Bank (EIB) Israel, June 19, 2018 -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of M-001, a clinical phase Universal Influenza Vaccine candidate, announced today the receipt of a 6 million disbursem
Read more →SCNIFirst Quarter 2018 Financial
First Quarter 2018 Financial NESS ZIONA, Israel, May 29, 2018 -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, today announced its financial results f
Read more →SCNIBiondVax Announces Fourth Quarter and Full Year 2017 Financial Results and Update
BiondVax Announces Fourth Quarter and Full Year 2017 Financial Results and NESS ZIONA, Israel, April 30, 2018 -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine c
Read more →SCNIBiondVax Begins NIH-Sponsored Phase 2 Clinical Trial of its Universal Flu Vaccine in the United States Ness Ziona, Israel
Begins NIH-Sponsored Phase 2 Clinical Trial its Universal Flu Vaccine in the United States Ziona, Israel - April 11, 2018 Pharmaceuticals Ltd. (Nasdaq: BVXV) reported today the first participant enrollment in the United States in a Phase 2 clinical trial of the company's univ
Read more →SCNIBiondVax Appoints CRO to Conduct Pivotal Clinical Efficacy Phase 3 Trial of its Novel Universal Flu Vaccine Candidate Ness Ziona, Israel
BiondVax Appoints CRO to Conduct Pivotal Clinical Efficacy Phase 3 Trial of its Novel Universal Flu Vaccine Candidate Ziona, Israel - March 13, 2018 Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the Universal Flu Vaccine candidate M-001, announced today the signing of a
Read more →SCNIOF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
Pharmaceuticals Ltd. OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS be held on, March 28, 2018 is hereby given that the annual and extraordinary general meeting of shareholders of BiondVax Pharmaceuticals Ltd. (the "Company"), will be held at the offices of Pearl
Read more →SCNIBiondVax plans Phase 3 Clinical Trial following receipt of Scientific Advice from the European Medicines Agency (EMA) Ness Ziona, Israel
BiondVax plans Phase 3 Clinical Trial following receipt of Scientific Advice from the European Medicines Agency (EMA) Ness Ziona, Israel - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV) announced today that the European Medicines Agency (EMA)'s Committee for Medicin
Read more →SCNIBiondVax's CEO Issues Letter to Shareholders Ness Ziona, Israel
CEO Issues Letter to Shareholders Ness Ziona, Israel - December 5, 2017 - BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today released a Letter from the CEO regarding recent activities and plans. 2017 Highlights and 2018 Plans: January 2017: Marius Nacht's aMoon P
Read more →SCNIProvides Third Quarter 2017 Financial Results and Update
Provides Third Quarter 2017 Financial Results and Update ZIONA, Israel, November 28, 2017 -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate,
Read more →SCNIBiondVax and NIH sign Clinical Trial
BiondVax and NIH sign Clinical Trial Agreement for a Phase 2 trial in the U.S. with BiondVax's Universal Flu Vaccine Ness Ziona, Israel - November 20, BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today announced the signing of the clinical trial agreement (CTA) fo
Read more →SCNIBiondVax Announces Closing of $10 Million Public Offering of American Depositary Shares and Exercise of Over-Allotment Option
BiondVax Announces Closing of $10 Million Public Offering of American Depositary Shares and Exercise of Over-Allotment Option NESS ZIONA, Israel, September 18, BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on deve
Read more →SCNIBiondVax Announces Pricing of Public Offering of American Depositary Shares
BiondVax Announces Pricing of Public Offering of American Depositary Shares NESS ZIONA, Israel, September 13, 2017 -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a univer
Read more →SCNIBiondVax Announces Public Offering of American Depositary Shares
Public Offering of American Depositary Shares NESS ZIONA, Israel, September 13, 2017 -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, toda
Read more →SCNIProvides Second Quarter 2017 Financial Results and Update
Provides Second Quarter 2017 Financial Results and Update ZIONA, Israel, August 31, 2017 -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, t
Read more →SCNIBiondVax Receives Additional Grant Funding Israel Innovation Authority Approves Additional Budget towards M-001 Flu Vaccine Development
Receives Additional Grant Funding Innovation Authority Approves Additional Budget towards M-001 Flu Vaccine Development ZIONA, ISRAEL, August 14, 2017 - Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that the Israel Innovation Authority (IIA), formerly known
Read more →SCNISigns Lease Agreement for Mid-Size Commercial Facility to Manufacture Universal Flu Vaccine
Signs Lease Agreement for Mid-Size Commercial Facility to Manufacture Universal Flu Vaccine Ziona, Israel - July 18, 2017 - Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV), developer of the Universal Flu Vaccine candidate M-001, today signed an agreement to lease approximately
Read more →SCNICEO Provides First Half 2017 General Corporate Update
CEO Provides First Half 2017 General Corporate Update Ziona, Israel - June 28, 2017 - Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV), developer of the Universal Flu Vaccine candidate M-001, today provided a general corporate update of its activities in the first half of 2017.
Read more →SCNICONTRACT IS MADE ON [ ] JUNE 2017 BETWEEN:
Contract number (FI No.): 85217 Serapis No.: 2015-0572 EUROPEAN INVESTMENT BANK AND BIONDVAX PHARMACEUTICAL LTD FINANCE CONTRACT BIONDVAX UNIVERSAL FLU VACCINE (IDFF) Clause Page 1. Interpretation and Definitions 2 2. Credit and Disbursements 10 3. The Loan 14 4. Remuneratio
Read more →SCNIBIONDVAX PHARMACEUTICALS LTD.
BIONDVAX PHARMACEUTICALS LTD. INTERIM FINANCIAL STATEMENTS AS OF MARCH 31, 2017 Page Condensed Interim Balance Sheets 2 Condensed Interim Statements of Comprehensive Income 3 Condensed Interim Statements of Changes in Shareholders' Equity 4 - 5 Condensed Interim Statements of
Read more →SCNIApproved for Grant from Israel's Ministry of Economy and Industry to
Approved for Grant from Israel's Ministry of Economy and Industry to Commercial Scale Production of its Universal Flu Vaccine Ziona, Israel - March 30, 2017 - Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today announced that the Israel Investment Center, a unit of the Gove
Read more →SCNIReceives $US 2.8 million Investment
Receives $US 2.8 million Investment Angels High Tech Investments Ltd. Shares BiondVax Vision of Commercializing World's First Universal Flu Vaccine Ziona, Israel - January 2, 2017 Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) is honored to announce that Angels High Tech Inv
Read more →SCNIBiondVax Phase 2b Trial Preliminary Safety Results: The Universal Flu Vaccine candidate is safe and well tolerated Ness Ziona, Israel
BiondVax Phase 2b Trial Preliminary Safety The Universal Flu Vaccine candidate is safe Ness Ziona, Israel - November 29, 2016 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV) today announced positive preliminary safety results from its European Phase 2b clinical tri
Read more →SCNIPosition Notice on behalf of the Board of Directors of BiondVax Pharmaceuticals Ltd. (the Company ) In connection with the Company's notice of an annual general shareholders meeting to be convened on
Notice on behalf of the Board of Directors of BiondVax Pharmaceuticals Ltd. (the "Company") connection with the Company's notice of an annual general shareholders meeting to be convened on September 22, 2016, and position notices received from a number of shareholders of the Co
Read more →SCNIShai Ashkenazi Appointed to BiondVax's Scientific Advisory Board
Shai Ashkenazi Appointed to BiondVax's Scientific Advisory Board An experienced clinician-researcher, Prof Ashkenazi has guided multiple vaccines through clinical and regulatory approval phases to market. Ness Ziona, Israel - September 7, 2016 - BiondVax Pharmaceuticals Ltd.
Read more →SCNIaccompanying notes are an integral part of the interim financial statements.
BIONDVAX PHARMACEUTICALS FINANCIAL STATEMENTS Page Condensed Interim Balance Sheets 2 Condensed Interim Statements of Comprehensive Income 3 Condensed Interim Statements of Changes in Shareholders' Equity 4 - 7 Condensed Interim Statements of Cash Flows 8 - 9 Notes to Condense
Read more →SCNIthousands, except per share data
BIONDVAX PHARMACEUTICALS FINANCIAL STATEMENTS Page Condensed Interim Balance Sheets 2 Condensed Interim Statements of Comprehensive Income 3 Condensed Interim Statements of Changes in Shareholders' Equity 4 - 5 Condensed Interim Statements of Cash Flows 6 - 7 Notes to Condense
Read more →SCNIBiondVax RECEIVES ADDITIONAL grant APPROVal Israel's National Authority for Technological Innovation to fund 40% of additional $0.9M budget towards Universal Flu Vaccine
RECEIVES ADDITIONAL grant APPROVal National Authority for Technological Innovation to fund 40% of additional $0.9M budget towards Universal Flu Vaccine ZIONA, ISRAEL, February 18, 2016. BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that the National
Read more →SCNI: BiondVax's Universal Flu Vaccine Receives ADDITIONAL US Patent Broadens BiondVax's global intellectual property portfolio
BiondVax's global intellectual property portfolio ZIONA, ISRAEL, January 27, 2016. BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) developer of a Universal Flu Vaccine currently undergoing late-stage 2 clinical trials, announced today that its patent application in th
Read more →SCNIPatent Approval for BiondVax: BiondVax Receives Approval for a Patent for its Universal Flu Vaccine in Israel The patent approval extends and strengthens BiondVax's international intellectual property portf
Approval for BiondVax: Receives Approval for a Patent for its Universal Flu Vaccine in Israel patent approval extends and strengthens BiondVax's international intellectual property portfolio Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) which is developing the Universal Fl
Read more →SCNIReceives Approval for Patent in Korea for its Universal Flu
Approval for BiondVax: Receives Approval for Patent in Korea for its Universal Flu patent approval extends and strengthens BiondVax's intellectual property portfolio internationally Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) which is developing the Universal Flu Vaccine,
Read more →SCNIQuarter 2015 Financial Results and Update
Quarter 2015 Financial Results and Update Ziona, Israel, November 9, 2015 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today
Read more →SCNIBiondVax Announces Successful Recruitment of the First Participants in a Phase IIb Clinical Trial in Europe with its Universal Flu Vaccine: Multimeric M-001 Trial in line with BiondVax clinical plan for Pha
Announces Successful Recruitment of the First Participants in a Phase IIb Clinical Trial in Europe with its Universal Flu Vaccine: in line with BiondVax clinical plan for Phase 3 trial in 2017/18 Ziona, Israel - October 21, 2015 - BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TA
Read more →SCNIBiondVax Establishes Capability for the Manufacture of Clinical Grade Universal Flu Vaccine for Phase III Clinical Trials Selects Cytovance Biologics Inc. for the production of clinical batches of M-001 Nes
Establishes Capability for the Manufacture of Clinical Grade Universal Flu Vaccine for Cytovance Biologics Inc. for the production of clinical batches of M-001 Ziona, Israel - October 1, 2015 - BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that it ha
Read more →SCNIAnnounces Intent to Launch a Phase 2 Trial in the
Announces Intent to Launch a Phase 2 Trial in the States in Collaboration with the U.S. National Institutes of Health Ziona, Israel - September 2, 2015 - BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today announced the intent of the National Institute of Allergy an
Read more →SCNIBiondVax Announces Second Quarter 2015 Financial Results and Update Nes Ziona, Israel
Quarter 2015 Financial Results and Update Ziona, Israel, August 24, 2015 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today a
Read more →SCNIResults Show that BiondVax's Universal Flu Vaccine
Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 years ago Improves Immunogenicity against Current Flu H3N2 Epidemic Ness Ziona, Israel - August 3, 2015 - BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today announced it received the stat
Read more →SCNIBiondVax to Close Trading on NASDAQ on July
BiondVax to Close Trading on NASDAQ on July BiondVax launches a new investor relations website (www.biondvax.com) providing international investors with comprehensive information about the Company, progress Ness Ziona, Israel - July 2, 2015 - BiondVax Pharmaceuticals Ltd. (NA
Read more →SCNIBiondVax Presents BVX-006 Preliminary Phase II Results: The Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults Preliminary results of BVX-006 show that M-001 is well tolerated and p
BiondVax Presents BVX-006 Preliminary Phase II Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults results of BVX-006 show that M-001 is well tolerated and provides improved flu immunity by enhancing antibody responses to multiple strains
Read more →SCNIBiondVax Pharmaceuticals Ltd. Announces a Closing of Over-Allotment Option Ness Ziona, Israel
Pharmaceuticals Ltd. Announces a Closing of Over-Allotment Option Ziona, Israel, June 24, 2015 - BiondVax Pharmaceuticals Ltd. (TASE: BVXV, Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infecti
Read more →SCNIBiondVax Announces FDA Acceptance of IND Application for its Investigational Universal Flu Vaccine Nes Ziona, Israel
FDA Acceptance of IND Application for its Investigational Universal Flu Vaccine Nes Ziona, Israel - June 17, 2015 - BiondVax Pharmaceuticals Ltd. (TASE: BVXV, Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation
Read more →SCNIBiondVax to Present at Workshop on Immunoassay Standardization for Universal Flu Vaccines Organized in Cooperation with the NIH and EDUFULVAC The presentation will take place in London on June 18-19 as part of the Compan
to Present at Workshop on Immunoassay Standardization for Universal Flu Vaccines Organized in Cooperation with the NIH and EDUFULVAC presentation will take place in London on June 18-19 as part of the Company's participation in the UNISEC (Universal Influenza Vaccines Secured
Read more →SCNIBiondVax Selected as part of OCS/IATI Delegation to 2015 BIO International Convention in Philadelphia Nes Ziona, Israel
Selected as part of OCS/IATI Delegation 2015 BIO International Convention in Philadelphia Ziona, Israel, June 11, 2015 - BiondVax Pharmaceuticals Ltd. (TASE: BNDX, Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulat
Read more →SCNIBiondVax Announces First Quarter 2015 Financial Results Nes Ziona, Israel
Announces First Quarter 2015 Financial Results Ziona, Israel, June 1, 2015 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BNDX), a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today
Read more →SCNIBiondVax Pharmaceuticals Ltd. Announces Closing of U.S. Initial Public Offering Nes Ziona, Israel
BiondVax Pharmaceuticals Ltd. Announces Closing of U.S. Initial Public Offering Nes Ziona, Israel, May 15, 2015 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV and BVXVW), a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation ther
Read more →SCNIBiondVax Pharmaceuticals Ltd. Announces Pricing of U.S. Initial Public Offering of 1,910,000 ADSs and Warrants to Purchase 1,910,000 ADSs
Pharmaceuticals Ltd. Announces Pricing of U.S. Initial Public Offering of 1,910,000 ADSs and Warrants to Purchase 1,910,000 ADSs RECHOVOT, Israel, May 11, 2015 (GLOBE NEWSWIRE) -- BiondVax Pharmaceuticals Ltd (BVXV) (Nasdaq:BVXVW), a clinical stage biopharmaceutical company foc
Read more →Competitive Position
How SCNI ranks across every disease it competes inCompetitive Position is a premium feature
See how SCNI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial